ADMA Biologics Inc ADMA
9.38
(0.14)
(1.47%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 13.0×
Follow ADMA
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 41.90% | 43.30% | 35.56% | 63.17% |
+8 more TTM periods Free account |
|
| 27.19% | 28.13% | 26.40% | 43.67% | ||
ROIC |
29.78% | 29.70% | 25.69% | 23.23% | |
Return on Tangible Assets |
32.55% | 32.90% | 31.80% | 50.39% | |
Average Days of Receivables |
98.49 | 97.26 | 113.35 | 102.85 | |
Free Cash Flow per Share |
0.51 | 0.48 | 0.12 | 0.17 | |
Free Cash Flow |
116.22 | 112.55 | 27.51 | 40.61 | |
Capital Expenditures |
(20.50) | (15.77) | (22.89) | (24.36) | |
Piotroski F-Score |
4.00 | 4.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
18.40% | 17.62% | 7.86% | 11.36% | |
Accounts Receivable Turnover |
4.13 | 4.33 | 4.90 | 5.20 | |
Accounts Payable Turnover |
5.88 | 9.60 | 10.17 | 11.05 | |
Inventory Turnover |
0.84 | 1.00 | 1.15 | 1.20 | |
Average Days of Payables |
64.04 | 37.94 | 37.81 | 39.62 | |
Days of Inventory on Hand |
483.11 | 410.57 | 346.63 | 324.41 | |
Tax Rate |
(0.22) | (0.20) | (0.20) | 0.34 | |
Research and Development Expense of Revenue |
2.25% | 1.28% | 0.93% | 0.77% | |
Selling, General and Administrative Expense of Revenue |
19.28% | 18.48% | 17.95% | 18.71% | |
Share Based Compensation of Revenue |
4.47% | 4.26% | 3.93% | 4.11% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.78 | 0.34 | 0.31 | |
Depreciation/Fixed assets |
0.12 | 0.13 | 0.13 | 0.12 | |
Capex/Depreciation |
(2.47) | (1.85) | (2.64) | (2.84) | |
Revenue per Share |
2.24 | 2.16 | 2.14 | 2.05 | |
Operating CF per Share |
0.60 | 0.54 | 0.21 | 0.27 | |
Capex per Share |
(0.09) | (0.07) | (0.10) | (0.10) | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.05 | |
Net Profit Margin |
32.98% | 32.43% | 28.80% | 42.87% |
Columns are period end dates